The success of copyright’s blockbuster initially sparked a surge for pharma, however recent changes present a murky outlook for investors. Off-patent competitors are reducing revenue, and continued patent challenges add more complexity to the landscape. While some companies may still see gains from complementary offerings, the broader trajectory